- This topic has 2 replies, 3 voices, and was last updated 3 years, 9 months ago by
.
-
Posts
-
In a short period of time, there has been a rapid increase in the interest and availability of CBD, as well as other cannabis derived products. We are gaining more knowledge and understanding of the safety profile of CBD and many compounds derived from cannabis. The FDA views these questions as an opportunity to develop new, scientific methods to build on and inform the public of new information.
The FDA evaluates CBD in the same manner as it does any substance that they regulate. They follow a regulatory process defined by both law, and also scientific evidence as the basis for their regulations and for the information that they communicate about a particular substance. They have voiced concerns and questions regarding the science, safety, efficacy and quality of cannabis products based on current research and evidence. More data are needed in the area of long term effects of CBD products. This will be conducted by the FDA and other public health agencies to make informed decisions that will have an impact on public health.
There is also a notable public health opportunity to use new sources of data and rigorously analytical methods to increase the safety profile and use of CBD and its related products. The FDA can contribute a unique expertise to evaluate data from various sources to make informed, regulatory decisions. The agency believes that real world data, RWD, on CBD use and safety plays an influential role along with data from other types of trials to augment their agency\’s understanding of CBD.
- You must be logged in to reply to this topic.